# Orion Energy Systems, Inc.: financial statements, quarterly

OESX · Nasdaq · CIK 1409375 · [Technology](/sectors/technology.md) · fiscal year ends Mar 31

Pages: [Overview](/companies/oesx.md) · [Financials](/companies/oesx/financials.md) · [Filings](/companies/oesx/filings.md) · [Insiders](/companies/oesx/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/oesx/financials.md?period=annual).

## Income statement

| Line item | Unit | Q2 FY2024 (2023-09-30) | Q3 FY2024 (2023-12-31) | Q4 FY2024 (2024-03-31) | Q1 FY2025 (2024-06-30) | Q2 FY2025 (2024-09-30) | Q3 FY2025 (2024-12-31) | Q4 FY2025 (2025-03-31) | Q1 FY2026 (2025-06-30) | Q2 FY2026 (2025-09-30) | Q3 FY2026 (2025-12-31) | Q4 FY2026 (2026-03-31) | Q1 FY2027 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [20.6](/filings/0000950170-24-122360.md) | [26.0](/filings/0000950170-25-017947.md) | [26.4](/filings/0000950170-24-072435.md) | [19.9](/filings/0000950170-25-104003.md) | [19.4](/filings/0001193125-25-266990.md) | [19.6](/filings/0001193125-26-039420.md) | [20.9 d](/filings/0001193125-26-257468.md) | [19.6](/filings/0001193125-26-335206.md) | [19.9](/filings/0001193125-25-266990.md) | [21.1](/filings/0001193125-26-039420.md) | [25.7 d](/filings/0001193125-26-257468.md) | [25.7](/filings/0001193125-26-335206.md) |
| Cost of revenue | $m | [16.0](/filings/0000950170-24-122360.md) | [19.6](/filings/0000950170-25-017947.md) | [19.6 d](/filings/0001193125-26-257468.md) | [15.6](/filings/0000950170-25-104003.md) | [14.9](/filings/0001193125-25-266990.md) | [13.8](/filings/0001193125-26-039420.md) | [15.1 d](/filings/0001193125-26-257468.md) | [13.7](/filings/0001193125-26-335206.md) | [13.7](/filings/0001193125-25-266990.md) | [14.6](/filings/0001193125-26-039420.md) | [16.2 d](/filings/0001193125-26-257468.md) | [16.8](/filings/0001193125-26-335206.md) |
| Gross profit | $m | [4.6](/filings/0000950170-24-122360.md) | [6.4](/filings/0000950170-25-017947.md) | [6.8](/filings/0000950170-24-072435.md) | [4.3](/filings/0000950170-25-104003.md) | [4.5](/filings/0001193125-25-266990.md) | [5.8](/filings/0001193125-26-039420.md) | [5.7 d](/filings/0001193125-26-257468.md) | [5.9](/filings/0001193125-26-335206.md) | [6.2](/filings/0001193125-25-266990.md) | [6.5](/filings/0001193125-26-039420.md) | [9.5 d](/filings/0001193125-26-257468.md) | [8.9](/filings/0001193125-26-335206.md) |
| Research and development | $m | [0.4](/filings/0000950170-24-122360.md) | [0.3](/filings/0000950170-25-017947.md) | [0.3 d](/filings/0001193125-26-257468.md) | [0.3](/filings/0000950170-25-104003.md) | [0.3](/filings/0001193125-25-266990.md) | [0.3](/filings/0001193125-26-039420.md) | [0.4 d](/filings/0001193125-26-257468.md) | [0.2](/filings/0001193125-26-335206.md) | [0.2](/filings/0001193125-25-266990.md) | [0.2](/filings/0001193125-26-039420.md) | [0.3 d](/filings/0001193125-26-257468.md) | [0.3](/filings/0001193125-26-335206.md) |
| Operating income | $m | [(4.2)](/filings/0000950170-24-122360.md) | [(2.1)](/filings/0000950170-25-017947.md) | [1.8 d](/filings/0001193125-26-257468.md) | [(3.4)](/filings/0000950170-25-104003.md) | [(3.3)](/filings/0001193125-25-266990.md) | [(1.2)](/filings/0001193125-26-039420.md) | [(2.6) d](/filings/0001193125-26-257468.md) | [(1.0)](/filings/0001193125-26-335206.md) | [(0.2)](/filings/0001193125-25-266990.md) | [0.4](/filings/0001193125-26-039420.md) | [(0.8) d](/filings/0001193125-26-257468.md) | [2.1](/filings/0001193125-26-335206.md) |
| Interest expense | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Income tax | $m | [0.0](/filings/0000950170-24-122360.md) | [0.0](/filings/0000950170-25-017947.md) | [(0.0) d](/filings/0001193125-26-257468.md) | [0.0](/filings/0000950170-25-104003.md) | [0.0](/filings/0001193125-25-266990.md) | [0.0](/filings/0001193125-26-039420.md) | [(0.0) d](/filings/0001193125-26-257468.md) | [(0.0)](/filings/0001193125-26-335206.md) | [0.0](/filings/0001193125-25-266990.md) | [0.0](/filings/0001193125-26-039420.md) | [0.0 d](/filings/0001193125-26-257468.md) | [0.0](/filings/0001193125-26-335206.md) |
| Net income | $m | [(4.4)](/filings/0000950170-25-017947.md) | [(2.3)](/filings/0000950170-25-017947.md) | [1.6](/filings/0000950170-24-072435.md) | [(3.8)](/filings/0001193125-26-039420.md) | [(3.6)](/filings/0001193125-26-039420.md) | [(1.5)](/filings/0001193125-26-039420.md) | [(2.9) d](/filings/0001193125-26-257468.md) | [(1.2)](/filings/0001193125-26-335206.md) | [(0.6)](/filings/0001193125-26-039420.md) | [0.2](/filings/0001193125-26-039420.md) | [(1.5) d](/filings/0001193125-26-257468.md) | [2.0](/filings/0001193125-26-335206.md) |
| Diluted EPS | $ per share | [(0.14)](/filings/0000950170-24-122360.md) | [(0.07)](/filings/0000950170-25-017947.md) | [0.05](/filings/0000950170-24-072435.md) | [(0.12)](/filings/0000950170-25-104003.md) | [(1.10)](/filings/0001193125-25-266990.md) | [(0.46)](/filings/0001193125-26-039420.md) | not reported | [(0.37)](/filings/0001193125-26-335206.md) | [(0.17)](/filings/0001193125-25-266990.md) | [0.04](/filings/0001193125-26-039420.md) | not reported | [0.47](/filings/0001193125-26-335206.md) |
| Basic EPS | $ per share | [(0.14)](/filings/0000950170-24-122360.md) | [(0.07)](/filings/0000950170-25-017947.md) | [0.05](/filings/0000950170-24-072435.md) | [(0.12)](/filings/0000950170-25-104003.md) | [(1.10)](/filings/0001193125-25-266990.md) | [(0.46)](/filings/0001193125-26-039420.md) | not reported | [(0.37)](/filings/0001193125-26-335206.md) | [(0.17)](/filings/0001193125-25-266990.md) | [0.05](/filings/0001193125-26-039420.md) | not reported | [0.48](/filings/0001193125-26-335206.md) |

- Revenue: us-gaap:Revenues
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: not reported
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q2 FY2024 (2023-09-30) | Q3 FY2024 (2023-12-31) | FY2024 (2024-03-31) | Q1 FY2025 (2024-06-30) | Q2 FY2025 (2024-09-30) | Q3 FY2025 (2024-12-31) | FY2025 (2025-03-31) | Q1 FY2026 (2025-06-30) | Q2 FY2026 (2025-09-30) | Q3 FY2026 (2025-12-31) | FY2026 (2026-03-31) | Q1 FY2027 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [4.0](/filings/0000950170-23-061523.md) | [5.0](/filings/0000950170-24-012204.md) | [5.2](/filings/0000950170-25-090385.md) | [5.7](/filings/0000950170-24-092909.md) | [5.4](/filings/0000950170-24-122360.md) | [7.5](/filings/0000950170-25-017947.md) | [6.0](/filings/0001193125-26-257468.md) | [3.6](/filings/0000950170-25-104003.md) | [5.2](/filings/0001193125-25-266990.md) | [4.7](/filings/0001193125-26-039420.md) | [3.3](/filings/0001193125-26-335206.md) | [5.2](/filings/0001193125-26-335206.md) |
| Current assets | $m | [45.3](/filings/0000950170-23-061523.md) | [45.7](/filings/0000950170-24-012204.md) | [44.8](/filings/0000950170-25-090385.md) | [42.1](/filings/0000950170-24-092909.md) | [40.0](/filings/0000950170-24-122360.md) | [37.1](/filings/0000950170-25-017947.md) | [35.5](/filings/0001193125-26-257468.md) | [32.7](/filings/0000950170-25-104003.md) | [32.0](/filings/0001193125-25-266990.md) | [32.8](/filings/0001193125-26-039420.md) | [37.7](/filings/0001193125-26-335206.md) | [39.2](/filings/0001193125-26-335206.md) |
| Total assets | $m | [65.8](/filings/0000950170-23-061523.md) | [65.4](/filings/0000950170-24-012204.md) | [63.2](/filings/0000950170-25-090385.md) | [59.8](/filings/0000950170-24-092909.md) | [56.3](/filings/0000950170-24-122360.md) | [52.7](/filings/0000950170-25-017947.md) | [52.5](/filings/0001193125-26-257468.md) | [49.0](/filings/0000950170-25-104003.md) | [47.9](/filings/0001193125-25-266990.md) | [48.3](/filings/0001193125-26-039420.md) | [51.6](/filings/0001193125-26-335206.md) | [53.3](/filings/0001193125-26-335206.md) |
| Current liabilities | $m | [29.0](/filings/0000950170-23-061523.md) | [30.7](/filings/0000950170-24-012204.md) | [28.1](/filings/0000950170-25-090385.md) | [24.8](/filings/0000950170-24-092909.md) | [26.9](/filings/0000950170-24-122360.md) | [26.6](/filings/0000950170-25-017947.md) | [26.8](/filings/0001193125-26-257468.md) | [26.6](/filings/0000950170-25-104003.md) | [24.0](/filings/0001193125-25-266990.md) | [24.2](/filings/0001193125-26-039420.md) | [26.7](/filings/0001193125-26-335206.md) | [25.6](/filings/0001193125-26-335206.md) |
| Total liabilities | $m | [43.2](/filings/0000950170-23-061523.md) | [44.8](/filings/0000950170-24-012204.md) | [40.6](/filings/0000950170-25-090385.md) | [40.7](/filings/0000950170-24-092909.md) | [40.5](/filings/0000950170-24-122360.md) | [38.2](/filings/0000950170-25-017947.md) | [40.6](/filings/0001193125-26-257468.md) | [38.2](/filings/0000950170-25-104003.md) | [36.5](/filings/0001193125-25-266990.md) | [36.4](/filings/0001193125-26-039420.md) | [35.0](/filings/0001193125-26-335206.md) | [34.6](/filings/0001193125-26-335206.md) |
| Long-term debt | $m | [10.0](/filings/0000950170-23-061523.md) | [10.6](/filings/0000950170-25-017947.md) | [10.0](/filings/0000950170-25-090385.md) | [13.3](/filings/0000950170-24-092909.md) | [12.2](/filings/0000950170-24-122360.md) | not reported | [10.0](/filings/0001193125-26-257468.md) | [8.1](/filings/0000950170-25-104003.md) | [9.3](/filings/0001193125-25-266990.md) | [9.0](/filings/0001193125-26-039420.md) | [5.6](/filings/0001193125-26-335206.md) | [6.3](/filings/0001193125-26-335206.md) |
| Current portion of debt | $m | [0.0](/filings/0000950170-23-061523.md) | [0.4](/filings/0000950170-25-017947.md) | [0.0](/filings/0000950170-25-090385.md) | [0.3](/filings/0000950170-24-092909.md) | [0.4](/filings/0000950170-24-122360.md) | [0.4](/filings/0000950170-25-017947.md) | [0.4](/filings/0001193125-26-257468.md) | [0.4](/filings/0000950170-25-104003.md) | [0.7](/filings/0001193125-25-266990.md) | [0.8](/filings/0001193125-26-039420.md) | [0.4](/filings/0001193125-26-335206.md) | [0.3](/filings/0001193125-26-335206.md) |
| Shareholders' equity | $m | [22.6](/filings/0000950170-25-017947.md) | [20.7](/filings/0000950170-25-017947.md) | [22.5](/filings/0001193125-26-257468.md) | [19.1](/filings/0001193125-26-039420.md) | [15.8](/filings/0001193125-26-039420.md) | [14.5](/filings/0001193125-26-039420.md) | [11.9](/filings/0001193125-26-335206.md) | [10.8](/filings/0001193125-26-335206.md) | [11.4](/filings/0001193125-26-039420.md) | [11.8](/filings/0001193125-26-039420.md) | [16.6](/filings/0001193125-26-335206.md) | [18.7](/filings/0001193125-26-335206.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Current portion of debt: us-gaap:LongTermDebtCurrent
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q2 FY2024 (2023-09-30) | Q3 FY2024 (2023-12-31) | Q4 FY2024 (2024-03-31) | Q1 FY2025 (2024-06-30) | Q2 FY2025 (2024-09-30) | Q3 FY2025 (2024-12-31) | Q4 FY2025 (2025-03-31) | Q1 FY2026 (2025-06-30) | Q2 FY2026 (2025-09-30) | Q3 FY2026 (2025-12-31) | Q4 FY2026 (2026-03-31) | Q1 FY2027 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [(3,988) d](/filings/0000950170-24-122360.md) | [1,048 d](/filings/0000950170-25-017947.md) | [175 d](/filings/0001193125-26-257468.md) | [(2,962)](/filings/0000950170-25-104003.md) | [498 d](/filings/0001193125-25-266990.md) | [3,762 d](/filings/0001193125-26-039420.md) | [(699) d](/filings/0001193125-26-257468.md) | [(515)](/filings/0001193125-26-335206.md) | [1,819 d](/filings/0001193125-25-266990.md) | [(897) d](/filings/0001193125-26-039420.md) | [(1,486) d](/filings/0001193125-26-257468.md) | [1,352](/filings/0001193125-26-335206.md) |
| Capital expenditure | $k | [239 d](/filings/0000950170-24-122360.md) | [121 d](/filings/0000950170-25-017947.md) | [(31.0) d](/filings/0001193125-26-257468.md) | [24.0](/filings/0000950170-25-104003.md) | [5.0 d](/filings/0001193125-25-266990.md) | [19.0 d](/filings/0001193125-26-039420.md) | [51.0 d](/filings/0001193125-26-257468.md) | [55.0](/filings/0001193125-26-335206.md) | [255 d](/filings/0001193125-25-266990.md) | [(252) d](/filings/0001193125-26-039420.md) | [25.0 d](/filings/0001193125-26-257468.md) | [6.0](/filings/0001193125-26-335206.md) |
| Share repurchases | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: not reported

## Shares

| Line item | Unit | Q4 FY2023 (2023-03-31) | Q1 FY2024 (2023-06-30) | Q2 FY2024 (2023-09-30) | Q3 FY2024 (2023-12-31) | Q4 FY2024 (2024-03-31) | Q1 FY2025 (2024-06-30) | Q2 FY2025 (2024-09-30) | Q3 FY2025 (2024-12-31) | Q1 FY2026 (2025-06-30) | Q2 FY2026 (2025-09-30) | Q3 FY2026 (2025-12-31) | Q1 FY2027 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [32.3](/filings/0000950170-24-072435.md) | [32.3](/filings/0000950170-24-092909.md) | [32.5](/filings/0000950170-24-122360.md) | [32.5](/filings/0000950170-25-017947.md) | [34.0](/filings/0000950170-24-072435.md) | [32.6](/filings/0000950170-25-104003.md) | [3.3](/filings/0001193125-25-266990.md) | [3.3](/filings/0001193125-26-039420.md) | [3.3](/filings/0001193125-26-335206.md) | [3.5](/filings/0001193125-25-266990.md) | [3.6](/filings/0001193125-26-039420.md) | [4.2](/filings/0001193125-26-335206.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 4,089,286 at 2026-02-04, from the cover of the [10-Q filed 2026-08-05](/filings/0001193125-26-335206.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:39 ET. No prices; not investment advice.